AFP and metabolic dysfunction-associated steatotic liver disease: In cirrhosis, cost‐effective if incidence HCC >1.5% p‐y77. In compensated cirrhosis, ultrasound + AFP cost‐effective if HCC incidence >0.4% p‐y and adherence >19.5%78; for hepatitis B, if HCC risk >0.2% p‐y. No data with NAFLD; IR of HCC in NAFLD‐related cirrhosis of 3.78 per 100 person‐years (95% CI, 2.47–5.78; I2 = 93%) in a meta‐analysis79. MRI cost‐effective for annual HCC risk >3%.33 No studies in HIV